Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA)

Historical Holders from Q2 2018 to Q3 2025

Symbol
VRCA on Nasdaq
Type / Class
Equity / Common Stock, $0.0001 par value
Shares outstanding
92,448,158
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
568
Holdings value
$301
Number of holders
1
Number of sells
-50
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Caligan Partners LP 9.99% $7,769,760 15,856,653 Caligan Partners LP 31 Dec 2024
ARMISTICE CAPITAL, LLC 9.99% 0% $7,480,813 +$81,611 9,235,571 +1.1% Armistice Capital, LLC 31 Mar 2025
PERCEPTIVE ADVISORS LLC 1.6% -70% $725,926 -$1,592,338 1,481,481 -68.7% Perceptive Advisors LLC 31 Mar 2025

Institutional Holders of Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 568 $301 -$13,341,078 $0.5299 1
2025 Q2 24,695,954 $13,342,110 -$2,100,389 $0.5301 52
2025 Q1 29,469,428 $13,048,369 -$1,283,534 $0.4422 72
2024 Q4 30,028,982 $21,000,938 +$9,292,302 $0.7000 79
2024 Q3 14,834,226 $21,508,548 -$32,397,531 $1.45 77
2024 Q2 18,643,979 $135,914,431 +$6,591,352 $7.29 73
2024 Q1 17,749,027 $105,073,968 -$1,725,785 $5.92 61
2023 Q4 18,001,640 $131,764,630 +$23,720,799 $7.32 62
2023 Q3 15,050,197 $58,469,992 +$1,486,122 $3.88 66
2023 Q2 14,600,620 $84,243,730 +$9,028,680 $5.77 63
2023 Q1 12,947,808 $84,159,481 +$15,090,414 $6.50 60
2022 Q4 10,821,432 $29,758,148 -$1,572,823 $2.75 49
2022 Q3 10,245,689 $29,916,489 -$2,471,402 $2.92 46
2022 Q2 11,327,999 $21,748,342 +$3,203,973 $1.92 51
2022 Q1 8,884,415 $72,064,740 -$552,806 $8.11 47
2021 Q4 8,952,454 $81,996,119 -$7,321,125 $9.16 43
2021 Q3 9,169,116 $114,604,238 -$9,413,538 $12.50 49
2021 Q2 9,937,044 $112,291,153 -$1,689,115 $11.30 53
2021 Q1 9,927,525 $150,401,616 +$14,713,541 $15.15 51
2020 Q4 8,959,095 $103,116,539 -$681,856 $11.51 44
2020 Q3 8,930,028 $69,119,527 +$677,068 $7.74 46
2020 Q2 8,804,592 $96,937,883 -$278,437 $11.01 44
2020 Q1 8,833,450 $96,547,906 -$4,771,475 $10.93 45
2019 Q4 9,202,752 $144,059,393 -$4,086,412 $15.89 52
2019 Q3 9,265,491 $136,756,439 +$4,176,491 $14.76 42
2019 Q2 9,017,971 $104,753,394 +$2,578,213 $11.62 40
2019 Q1 8,816,628 $96,977,441 +$5,664,930 $10.81 40
2018 Q4 8,445,077 $68,825,024 -$1,838,933 $8.15 41
2018 Q3 8,239,628 $133,896,000 -$2,329,398 $16.25 45
2018 Q2 8,314,673 $164,045,000 +$164,044,999 $19.73 28